CD274 and neoplasm: In recent advancements, immunotherapies targeting various anti-tumor immune mechanisms, particularly therapies focused on the PD-1 and PD-L1 pathways, have emerged as frontline treatments for metastatic MCC (Harms et al. 2018; Becker et al. 2018).